3 Stocks Estimated To Be Trading Below Their Intrinsic Value In August 2026
Over the last 7 days, the United States market has risen by 1.0%, contributing to an impressive 18% increase over the past year, with earnings forecasted to grow by 17% annually. In such a robust environment, identifying stocks that are trading below their intrinsic value can offer investors potential opportunities for growth and diversification.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Workday (WDAY) | $175.29 | $343.71 | 49% |
| Tempus AI (TEM) | $54.61 | $108.06 | 49.5% |
| Symbotic (SYM) | $41.19 | $79.59 | 48.3% |
| OceanFirst Financial (OCFC) | $19.15 | $38.07 | 49.7% |
| Natera (NTRA) | $315.96 | $607.68 | 48% |
| Lumentum Holdings (LITE) | $932.47 | $1844.13 | 49.4% |
| HawkEye 360 (HAWK) | $24.73 | $48.00 | 48.5% |
| Haemonetics (HAE) | $91.34 | $175.73 | 48% |
| Fluence Energy (FLNC) | $13.20 | $26.05 | 49.3% |
| Advanced Energy Industries (AEIS) | $337.32 | $655.09 | 48.5% |
Let's take a closer look at a couple of our picks from the screened companies.
Seagate Technology Holdings (STX)
Overview: Seagate Technology Holdings plc is a company that provides data storage solutions across Singapore, the United States, the Netherlands, and internationally, with a market cap of approximately $185.97 billion.
Operations: The company's revenue primarily comes from the manufacture and distribution of storage solutions, totaling $12.20 billion.
Estimated Discount To Fair Value: 26.2%
Seagate Technology Holdings is trading significantly below its estimated future cash flow value, presenting a potential undervaluation. Despite high debt levels and recent share price volatility, the company reported robust financial performance with full-year sales of US$12.20 billion and net income of US$3.18 billion, showcasing strong earnings growth over the past year. Revenue and earnings are forecast to grow faster than the market average, supporting its investment appeal based on cash flows.
- Upon reviewing our latest growth report, Seagate Technology Holdings' projected financial performance appears quite optimistic.
- Navigate through the intricacies of Seagate Technology Holdings with our comprehensive financial health report here.
Zscaler (ZS)
Overview: Zscaler, Inc. is a global cloud security company with a market capitalization of approximately $28.87 billion.
Operations: The company's revenue primarily comes from sales of subscription services to its cloud platform and related support services, amounting to $3.17 billion.
Estimated Discount To Fair Value: 29.5%
Zscaler is trading 29.5% below its estimated fair value and more than 20% under its future cash flow value, suggesting potential undervaluation. Despite recent share price volatility and insider selling, the company forecasts strong revenue growth of 13.7% annually, outpacing the US market. Zscaler's strategic partnerships and innovations in AI-driven cybersecurity enhance its competitive edge as it aims for profitability within three years, further supporting its investment attractiveness based on cash flows.
- Our earnings growth report unveils the potential for significant increases in Zscaler's future results.
- Unlock comprehensive insights into our analysis of Zscaler stock in this financial health report.
Haemonetics (HAE)
Overview: Haemonetics Corporation is a medical technology company that offers a range of hospital technology solutions and has a market cap of approximately $3.97 billion.
Operations: The company's revenue segments include MedSurg, which generated $596.71 million.
Estimated Discount To Fair Value: 48%
Haemonetics, trading at US$91.34, is significantly undervalued based on discounted cash flow analysis, with an estimated fair value of US$175.73. Despite a high debt level and recent profit margin decline to 7.1% from 12.1%, earnings are projected to grow at 23.5% annually, surpassing the broader market's growth rate of 16.8%. Recent FDA approval for its VASCADE MVP XL system bolsters its product portfolio and future revenue potential amidst slower revenue growth forecasts compared to the market.
- Our expertly prepared growth report on Haemonetics implies its future financial outlook may be stronger than recent results.
- Click here and access our complete balance sheet health report to understand the dynamics of Haemonetics.
Taking Advantage
- Get an in-depth perspective on all 134 Undervalued US Stocks Based On Cash Flows by using our screener here.
- Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
- Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com